Francesco is a co-founder and Partner at Medicxi. Prior to Medicxi, Francesco was a Partner at Index Ventures for 19 years, having joined the firm in 1997 to launch its life sciences practice. Under his leadership, the asset-centric approach to life sciences investing was conceived and adopted. Francesco currently serves on the boards of a number of portfolio companies, including Centessa Pharmaceuticals, Rivus Pharmaceuticals, Levicept, Granular Therapeutics and Kaerus.
Francesco’s prior investments include CellZome (acquired by GlaxoSmithKline), GenMab (Copenhagen: GEN.CO), GenSight Biologics (Euronext: SIGHT), Micromet (acquired by Amgen), Minerva Neurosciences (NASDAQ:NERV), Molecular Partners (Swiss:MOLN.SW), PanGenetics (acquired by Abbott), Parallele Biosciences (acquired by Affymetrix), Profibrix (acquired by The Medicines Company), Versartis (NASDAQ:VSAR).
Francesco received a BA in Genetics and Microbiology from the University of Pavia and a PhD Molecular Biology from the University of Geneva. He conducted postdoctoral research at the Whitehead Institute at MIT and is a CFA Charterholder.
How do I contact Francesco De Rubertis?
Has Francesco De Rubertis been buying or selling shares of Centessa Pharmaceuticals?
Francesco De Rubertis has not been actively trading shares of Centessa Pharmaceuticals over the course of the past ninety days. Most recently, on Wednesday, December 1st, Rubertis Francesco De bought 60,304 shares of Centessa Pharmaceuticals stock. The stock was acquired at an average cost of $12.62 per share, with a total value of $761,036.48. Learn More on Francesco De Rubertis' trading history.
Who are Centessa Pharmaceuticals' active insiders?
Are insiders buying or selling shares of Centessa Pharmaceuticals?
In the last year, insiders at the sold shares 12 times. They sold a total of 380,458 shares worth more than $5,855,386.13. The most recent insider tranaction occured on October, 25th when insider Gregory M Weinhoff sold 11,742 shares worth more than $180,591.96. Insiders at Centessa Pharmaceuticals own 11.6% of the company.
Learn More about insider trades at Centessa Pharmaceuticals. Information on this page was last updated on 10/25/2024.
